Delphi VC is an early-stage venture investor. Its psychedelic-field connection is participation in Beckley Psytech’s oversubscribed US$80 million Series B in 2021, backing the UK developer of 5-MeO-DMT (BPL-003) and low-dose psilocybin therapies.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage focus is not listed yet. Psychedelic-market posture: Psychedelic-Adjacent Focus.
Public Portfolio Examples
- Journey ColabSeries A - $12 million - Sep 7, 2021
Created from documented participation in 1 psychedelic financing round. Profile details beyond documented deals are unverified.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Stage focus is not listed yet.
Investment Focus Areas
Focus areas are not listed yet.
Recorded Investments
Sep 7, 2021
Series A - $12 million
Fenwick Represents Journey Colab in $12 Million Series A Financing